...
首页> 外文期刊>BMC Medical Genomics >Identification of potential therapeutic targets for atherosclerosis by analysing the gene signature related to different immune cells and immune regulators in atheromatous plaques
【24h】

Identification of potential therapeutic targets for atherosclerosis by analysing the gene signature related to different immune cells and immune regulators in atheromatous plaques

机译:通过分析与流管斑块不同免疫细胞和免疫调节剂相关的基因签名来鉴定动脉粥样硬化的潜在治疗靶

获取原文
           

摘要

Atherosclerosis is a chronic inflammatory disease that affects multiple arteries. Numerous studies have shown the inherent immune diversity in atheromatous plaques and suggest that the dysfunction of different immune cells plays an important role in atherosclerosis. However, few comprehensive bioinformatics analyses have investigated the potential coordinators that might orchestrate different immune cells to exacerbate atherosclerosis. Immune infiltration of 69 atheromatous plaques from different arterial beds in GSE100927 were explored by single-sample-gene-set enrichment analysis (presented as ssGSEA scores), ESTIMATE algorithm (presented as immune scores) and CIBERSORT algorithm (presented as relative fractions of 22 types of immune cells) to divide these plaques into ImmuneScoreL cluster (of low immune infiltration) and ImmuneScoreH cluster (of high immune infiltration). Subsequently, comprehensive bioinformatics analyses including differentially-expressed-genes (DEGs) analysis, protein–protein interaction networks analysis, hub genes analysis, Gene-Ontology-terms and KEGG pathway enrichment analysis, gene set enrichment analysis, analysis of expression profiles of immune-related genes, correlation analysis between DEGs and hub genes and immune cells were conducted. GSE28829 was analysed to cross-validate the results in GSE100927. Immune-related pathways, including interferon-related pathways and PD-1 signalling, were highly enriched in the ImmuneScoreH cluster. HLA-related (except for HLA-DRB6) and immune checkpoint genes (IDO1, PDCD-1, CD274(PD-L1), CD47), RORC, IFNGR1, STAT1 and JAK2 were upregulated in the ImmuneScoreH cluster, whereas FTO, CRY1, RORB, and PER1 were downregulated. Atheromatous plaques in the ImmuneScoreH cluster had higher proportions of M0 macrophages and gamma delta T cells but lower proportions of plasma cells and monocytes (p??0.05). CAPG, CECR1, IL18, IGSF6, FBP1, HLA-DPA1 and MMP7 were commonly related to these immune cells. In addition, the advanced-stage carotid plaques in GSE28829 exhibited higher immune infiltration than early-stage carotid plaques. Atheromatous plaques with higher immune scores were likely at a more clinically advanced stage. The progression of atherosclerosis might be related to CAPG, IGSF6, IL18, CECR1, FBP1, MMP7, FTO, CRY1, RORB, RORC, PER1, HLA-DPA1 and immune-related pathways (IFN-γ pathway and PD-1 signalling pathway). These genes and pathways might play important roles in regulating immune cells such as M0 macrophages, gamma delta T cells, plasma cells and monocytes and might serve as potential therapeutic targets for atherosclerosis.
机译:动脉粥样硬化是一种影响多个动脉的慢性炎症疾病。众多研究表明了椎间盘斑的固有免疫多样性,并表明不同免疫细胞的功能障碍在动脉粥样硬化中起重要作用。然而,很少有综合的生物信息学分析研究了可能会协调不同免疫细胞以加剧动脉粥样硬化的潜在协调者。单样品基因集富集分析(呈现为SSGSEA评分),估算算法(呈现为免疫分数)和Cibersort算法(呈现为22种的相对分数免疫细胞)将这些斑块分成免疫血管簇(低免疫浸润)和免疫渗透簇(高免疫渗透)。随后,综合生物信息学分析包括差异表达基因(DEGS)分析,蛋白质 - 蛋白质相互作用网络分析,集线基因分析,基因本发明术语和KEGG途径浓缩分析,基因设定富集分析,免疫的表达谱分析进行了相关基因,进行了DEGS和轮毂基因和免疫细胞之间的相关分析。分析GSE28829以交叉验证GSE100927的结果。免疫相关途径,包括干扰素相关的途径和PD-1信号传导,在免疫群体中高度富集。 HLA相关(除HLA-DRB6外)和免疫检查点基因(IDO1,PDCD-1,CD274(PD-L1),RORC,IFNGR1,STAT1和JAK2在免疫群中上调,而FTO,CRY1,下调rorb和per1。免疫调节器簇中的斑鸠斑块具有较高的M0巨噬细胞和γδT细胞的比例,但较低比例的血浆细胞和单核细胞(p≤≤0.05)。 CAPG,CECR1,IL18,IGSF6,FBP1,HLA-DPA1和MMP7通常与这些免疫细胞有关。此外,GSE28829中的晚期颈动脉斑块表现出比早期颈动脉斑块更高的免疫浸润。具有较高免疫分数的斑鸠斑块可能在更临床上升的阶段。动脉粥样硬化的进展可能与CAPG,IGSF6,IL18,CECR1,FBP1,MMP7,FTO,CRY1,RORB,RORC,PER1,HLA-DPA1和免疫相关途径(IFN-γ途径和PD-1信号通路)有关。这些基因和途径可能在调节免疫细胞如M0巨噬细胞,γδT细胞,血浆细胞和单核细胞中发挥重要作用,并且可以作为动脉粥样硬化的潜在治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号